Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine

International Journal of Clinical Practice

Volumn 62, Issue 6, 2008, Pages 925-931

  Coyne, K S ^a   Elinoff, V ^b   Gordon, D A ^c   Deng, D Y ^d   Brodsky, M ^e   Glasser, D B ^e   Jumadilova, Z ^e   Carlsson, M ^e  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Regional Clinical Research Inc   (United States)

^c Chesapeake Urology Center for Continence and Pelvic Floor Disorders ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOLTERODINE;

ADULT; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SYMPTOM; TREATMENT RESPONSE; URINE INCONTINENCE;

BENZHYDRYL COMPOUNDS; CRESOLS; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; PHENYLPROPANOLAMINE; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 43749116211     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01778.x     Document Type: Article

References (33)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003 61 : 37 49.
2. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 20 : 327 36.
3. Hu TW, Wagner TH, Bentkover JD et al. Estimated economic costs of overactive bladder in the United States. Urology 2003 61 : 1123 8.
4. Hu TW, Wagner TH, Bentkover JD et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004 63 : 461 5.
5. Coyne KS, Payne C, Bhattacharyya SK et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004 7 : 455 63.
6. MacDiarmid S, Rosenberg M. Overactive bladder in women: symptom impact and treatment expectations. Curr Med Res Opin 2005 21 : 1413 21.
7. Coyne KS, Zhou Z, Bhattacharyya SK et al. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 2003 92 : 948 54.
8. Coyne KS, Zhou Z, Thompson C, Versi E. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 2003 92 : 731 5.
9. Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001 57 : 1044 50.
10. Abrams P, Kelleher C, Lerr L, Rogers R. Overactive bladder significantly affects quality of life. Am J Manag Care 2000 6 : S580 90.
11. Irwin DE, Milsom I, Kopp Z et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006 97 : 96 100.
12. Patient Reported Outcome Harmonization Group. Important Issues in PRO Research Continued Discussions, 2002. http://www.eriqua-project.com/pro-harmo/ meetings.htm (accessed June 2007).
13. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999 2 : 113 27.
14. Fairclough DL. Patient reported outcomes as endpoints in medical research. Stat Methods Med Res 2004 13 : 115 38.
15. Wiklund I. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life. Fundam Clin Pharmacol 2004 18 : 351 63.
16. Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. Int J Fertil Womens Med 1999 44 : 56 66.
17. Rosenberg MT. Overactive bladder made ridiculously simple? Int J Clin Pract 2006 60 : 631 4.
18. Abrams P, Artibani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006 68 (Suppl. 2A 17 28.
19. Brubaker L, Chapple C, Coyne K, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006 68 (Suppl. 2A 3 8.
20. Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002 8 : S608 15.
21. Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol 2004 22 : 251 6.
22. Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002 24 : 616 28.
23. Roberts R, Bavendam T, Glasser DB et al. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int J Clin Pract 2006 60 : 752 8.
24. Elinoff V, Bavendam T, Glasser DB et al. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 2006 60 : 745 51.
25. Matza LS, Thompson CL, Krasnow J et al. Test-retest reliability of four questionnaires for patients with overactive bladder: the Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ). Neurourol Urodyn 2005 24 : 215 25.
26. Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002 11 : 563 74.
27. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006 49 : 1079 86.
28. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Hillsdale, NJ : Lawrence Erlbaum Associates, 1988.
29. van Kerrebroeck P, Coyne KS, Kopp Z et al. Tolterodine Extended Release (ER) for Overactive Bladder (OAB): Correlations Among Improvements in Objective Symptoms, Patient Perception of Bladder Condition (PPBC), and Health-Related Quality of Life (HRQL) [Abstract 007]. Paris : European Association of Urology, 5-8 April 2006.
30. Willke RJ, Burke LB, Erickson P. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 2004 25 : 535 52.
31. Office of New Drugs, Office of Medical Policy. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. http://www.fda.gov/cder/guidance/5460dft.htm (accessed March 2006).
32. Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 2005 14 : 849 55.
33. Coyne K, Tubaro A, Brubaker L, Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder. Urology 2006 68 (Suppl. 2A 9 16.